WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	74.91B +123.2%
Revenue (ttm)	5.58B +82.0%
Net Income	1.45B +123.2%
EPS	1.12 +107.4%
Shares Out	1.26B
PE Ratio	53.25
Forward PE	35.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,389,766
Average Volume	4,630,839
Open	56.85
Previous Close	57.65
Day's Range	56.05 - 59.65
52-Week Range	24.70 - 85.50
Beta	-2.10
RSI	43.23
Earnings Date	Mar 23, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Lab...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,270
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY